NorTrials networking event at ESC 2025
29 August 2025, 12:30 - 14:30 GMT
Seminar
Norway, through NorTrials and Innovation Norway, is bringing the international pharma industry together with the Norwegian specialist healthcare system, held in connection with ESC Congress 2025 in Madrid — where we’ll explore how Norway is advancing the future of cardiovascular clinical trials through precision medicine, cutting-edge infrastructure and a nationally coordinated strategy.
Why Norway?
Norway is advancing as a strategic partner for clinical trials — with world-class infrastructure, renowned medical expertise and a strong national commitment to innovation in cardiology and precision medicine.
This session highlights Norway’s strengths in clinical research and our new national strategy to become a leading country of excellence for cardiovascular trials.
“Participation is by direct invitation only — please register your interest by 15 August 2025.”
Who you will meet?
- The Norwegian healthcare system
- Industry leaders from Norway’s life sciences sector
- NorTrials – Norway’s national entry point for global trial sponsors
- Innovation Norway
What Sets Norway Apart?
- Internationally recognised clinicians and clinical trial units
- Unique access to integrated health registries and biobanks
- National infrastructure for precision and molecular diagnostics
- Strong public-private collaboration models
- High patient engagement and trial participation rates
- A well-structured, high-performing specialist health system
Meet us to learn how Norway’s coordinated approach is unlocking new possibilities for international trial sponsors — and why the next generation of cardiovascular trials might just start north of the ordinary.
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.